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SUMMARY
Objective: To evaluate the breast histomorphometric changes in rats treated with estro-
gen and/or progestogen for a short period of time. Methods: Forty oophorectomized 
rats were divided into four groups: GC, vehicle; GE, treated with estradiol benzoate 
(37.6 mg/animal); GP, treated with medroxyprogesterone acetate (11.2 mg/animal); and 
GEP, treated with estradiol benzoate (37.6  mg/animal) plus medroxyprogesterone ac-
etate (11.28 mg/animal). In GE group, estradiol was administered subcutaneously for 
seven days; in GEP group, estradiol was administered once in a day for the first seven 
days and the progestogen over the next 23 days both subcutaneously. Twenty-four hours 
after the last hormone administration, the animals were killed upon deep anesthesia and 
the first inguinal breasts were removed, fixed in 10% formaldehyde and processed to be 
included in paraffin, with the sections being stained by hematoxylin-eosin. Morphology 
and the area occupied by mammary parenchyma were assessed, with the data under-
going analysis of variance followed by the Kruskal-Wallis test (p < 0.05). Results: The 
control group breasts were found atrophic and, in GE and GEP group animals, typical 
alveoli with secretion inside are present; in progestogen-treated animals (GP), alveoli 
formed by large cells occupying almost the entire alveolar lumen are noted. Morpho-
metric analysis showed a larger mammary parenchyma area in hormone-treated ani-
mals (GE = GP > GEP > GC; p < 0.05). Conclusion: Estradiol and progestogen had a 
proliferative effect on mammary parenchyma. However, prior estradiol administration 
changes the progestogen action on rat mammary tissue.
Keywords: Breast; rats; estradiol; medroxyprogesterone 17-acetate; hormone replace-
ment therapy.
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INTRODUCTION
The transition from the reproductive period into the non-
reproductive period in women, which is known as cli-
macteric, is marked by important endocrine, somatic, and 
psychic changes due to the reduced ovarian hormone pro-
duction. This period landmark is menopause, where the 
last menstruation date was 12 months before1,2.
For most women, this phase can bring symptoms such 
as hot flashes, neuropsychiatric findings, vaginal dryness 
and others3,4.
Replacement hormone therapy (HT) can provide sev-
eral benefits for women, especially in post-menopause, 
and has been shown effective in alleviating the main symp-
toms resulting from hypoestrogenism5-7. However, the oc-
currence of long-term adverse effects by using estropro-
gestative therapy is reported, especially an increased breast 
cancer risk8. Actually, many epidemiological studies have 
reported an increased breast cancer risk, with this risk be-
ing higher when estrogen-progestogen combinations are 
used than with estrogens alone9. The breast is a structure 
responding variably to steroid hormones. Its hormonal in-
teraction is complex; sexual steroids can act by autocrine, 
paracrine or endocrine routes. Under the action of these 
steroid hormones, mammary tissue reaches its maximum 
development10,11. The hormone action on target-organs re-
sults from their binding intracellular receptors, modulat-
ing gene expression and hence specific protein synthesis12.
There is evidence that estrogens stimulate ductal 
growth13,14. However, for some authors, estrogens produce 
breast epithelium atrophy15. Progestogens added to estro-
genic therapy do not reduce breast cancer risk. There is 
further evidence that the combination might increase the 
breast epithelial cell proliferation16.
However, whether the acute treatment with either es-
trogens and progestogens alone or the combined therapy 
changes the breast proliferative pattern is debated. There-
fore, this paper aims at evaluating the histomorphologic 
and histomorphometric effects of estrogen and/or pro-
gestogen therapy on the mammary tissue of oophorecto-
mized adult rats.
METHODS
Forty Wistar (Rattus norvegicus albinus) EPM-1 lineage, 
adult, virgin and 90-day-old rats provided by the Cen-
tro de Desenvolvimento de Modelos de Experimentação 
(CEDEME) [Experimental Model Development Center] 
at the Universidade Federal de São Paulo – Escola Paulista 
de Medicina (Unifesp/EPM) were used. This study was ap-
proved by Unifesp/EPM Research Ethics Committee (Re-
port no. 0820/07).
The animals were maintained restricted to plastic cages 
in the Histology and Structural Biology Discipline vivar-
ium (Unifesp/EPM) with a controlled room temperature 
of 22°C and artificial lighting from fluorescent lamps, with 
a 12-hour light photoperiod (7 AM to 7 PM) and a 12-
hour dark photoperiod (7 PM to 7 AM); food and water 
ad libitum.
After a seven-day period, all animals underwent bilat-
eral oophorectomy and 30 days later they were randomly 
separated into four groups with 10 rats each, namely: GC, 
the animals were treated with corn oil (vehicle); GE, the 
animals were treated with estradiol benzoate (37.6  mg/
animal) subcutaneously for seven consecutive days; GP, 
animals were treated with medroxyprogesterone acetate 
(11.28  mg/animal) subcutaneously for 23 consecutive 
days; GEP, animals were treated with estradiol benzoate 
(37.5 mg/animal) for seven days followed by medroxypro-
gesterone acetate (11.28  mg/animal) for further 23 con-
secutive days. The hormones were administered in doses 
similar to those used in post-menopaused women17.
Twenty-four hours after the last administration, all the 
animals were given a xylazine (20  mg/kg) and ketamine 
(100  mg/kg) mixture intraperitoneally injected and the 
first inguinal pair of breasts was removed. Then the breasts 
were fixed in 10% formaldehyde and processed 24 hours 
later to be included in paraffin according to routine his-
tological methods. Four-micrometer (microtome LEICA 
– RM 2145) serial sections were obtained from the blocks 
and stained by hematoxylin and eosin for further histo-
morphologic and morphometric analysis. The area occu-
pied by mammary and adipose tissues was assigned for 
morphometric analysis. The imaging retrieval system used 
was made up by a light microscope (Carl Zeiss) attached 
to a high resolution camera (AxioCam- MRC, Carl Zeiss) 
and color video monitor (Samsung). The images acquired 
were evaluated by the imaging analysis software AxionVi-
sion REL 4.6 by Carl Zeiss. For this purpose, the portion 
occupied by mammary parenchyma and fat tissue was 
delimited in an area of 380 x 103 mm each section. Four 
near serial section were evaluated in each experimental 
animal, with a total area of 152 x 103 mm2 being evaluated 
in each study group. The analysis of variance (ANOVA) 
and the Kurskal-Wallis test were used to analyze the re-
sults achieved. The analyses were carried out by using the 
software Prisma (California, USA) and Excel (Microsoft). 
In all statistical testing, significance levels of 5% were used 
(_ ≤ 0.05).
RESULTS
A) Histomorphologic results: control group (GC) animal 
breast showed a high fat tissue concentration and scanty 
parenchyma where rudimentary ducts and alveoli could 
be identified (Figure  1A). Within the latter, yellow pig-
ment-laden macrophages could be identified. Yet in the 
estradiol-treated group (GE), a further developed paren-
chyma was observed, with dilated ducts and alveoli pre-
senting, the vast majority of them having an eosinophilic 
material (secretion) inside (Figure 1B).
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Figure 1 – Photomicrographs showing a portion of mammary 
tissue from oophorectomized rats (A), estradiol-treated rats 
(B), medroxyprogesterone-treated rats (C) or rats treated 
with a estradiol plus medroxyprogesterone combination 
(D). In A, a mammary duct and a rudimentary alveolus are 
observed (arrow). Otherwise, in B and D, estradiol is noticed 
to induce the formation of alveoli containing a secretion 
inside, while medroxyprogesterone alone (C) induces 
proliferation with no typical alveoli (Alv). H.E. 400X.
In the group treated with progesterone alone (GP), we 
noted numerous mitosis figures in the mammary paren-
chyma, with the cells being irregularly arranged. The ducts 
were lined by either a single-layer or a stratified cylindri-
cal epithelium with dense connective tissue surrounding 
them. On the other hand, alveoli were lined by a single-
layer cubic epithelium, whose rounded nuclei were dis-
placed down to the basal region and the cytoplasm was 
eosinophilic. No secretion was identified inside the ducts 
and/or alveoli (Figure 1C).
In the group treated with estradiol plus medroxypro-
gesterone (GEP), the histological feature was quite similar 
to that in the estrogen-treated group, i.e., it was made up 
by dilated ducts and alveoli containing a secretion inside. 
In this group (GEP), we noticed the alveoli had a lower 
size and the secretion present in the alveolus lumen was 
scarcer (Figure 1D).
B) Morphometry: the achieved data regarding the 
mammary parenchyma area in rats included in the several 
study groups are expressed in Table 1.
DISCUSSION
The information concerning the risks and benefits of 
post-menopausal hormone replacement creates questions 
and uncertainties. In spite of quantitative assessments for 
signs, symptoms, psychosocial aspects and hormone treat-
ment use, there is little information about the individual 
significance and Brazilian woman experience with these 
issues. The current paper tried to reproduce this hormone 
therapy effects by using estrogen and progestogen doses 
equivalent to those usually used in post-menopausal hor-
mone replacement. For this purpose, an allometric cal-
culation was made by equating the dose according to the 
rats’ weight and metabolism17.
From the hormone measurements used, our results 
showed there is a smaller mammary parenchyma and pro-
liferation area in oophorectomized animals that were not 
given hormones. However, a larger mammary parenchy-
ma was found in animals treated with either estradiol or 
medroxyprogesterone over the group receiving estradiol 
followed by medroxyprogesterone.
In animals receiving estradiol (all over the trial period 
or only on the first days on hormone therapy), we noticed 
alveoli containing a secretion inside. This fact would re-
sult from prolactin release by the pituitary gland under an 
estrogenic action; there would still be a gonadotropin se-
cretion inhibition18-20. Actually, our results bear out biopsy 
studies in post-menopausal woman breasts demonstrat-
ing higher epithelium proliferation in HT users compared 
with a non-hormone user group21,22. In these studies, most 
changes are found in the duct-terminal lobule unit where 
most breast tumors develop.
Experimental studies have also proved proliferative 
changes in 17-beta estradiol-treated rat breasts23. Some 
patients are known to report breast symptoms, such as 
breast pain, breast enlargement or increased consistency 
on palpation, resulting from estrogen action, when they 
are in the premenstrual phase. These phenomena are 
likely due to the trophic stimulus occurring in the post-
menopausal atrophic fibroglandular tissue24. Premeno-
pausal women are prone to have more ducto-glandular 
and fibrous tissue in the breasts rather than fat tissue. This 
ratio is inverted with time, reaching a postmenopausal 
near complete replacement by fat tissue25.
Study groups
GC GE GP GEP
Total occupied area 103 +m2 1,915.20 ± 133.30 11,948.72 ± 287.28 10,488.00 ± 342.21 7,546.80 ± 260.52
% occupied area 12.16 78.61 69.00 49.65
GC, control group; GE, estradiol group; GP, medroxyprogesterone group; GEP, estradiol and medroxyprogesterone-treated group (GE = GP > 
GEP > GC; p < 0.05).
Table 1 – Means, standard-deviations, and percentage of the area occupied by mammary parenchyma in oophorectomized 
rats treated with estradiol, medroxyprogesterone or an estradiol and medroxyprogesterone combination
BREAST HISTOMORPHOMETRY OF RATS TREATED WITH ESTROGEN AND/OR PROGESTOGEN
177Rev Assoc Med Bras 2011; 57(2):174-177
In our study, the finding that rat breasts had a differ-
ent morphologic behavior in animals receiving estradiol 
followed by medroxyprogesterone and in animals treated 
with medroxyprogesterone alone was outstanding. Pro-
gestogen alone induced increased mammary parenchyma, 
but with no typical alveolus formation. In contrast, the 
behavior was quite different in animals previously treat-
ed with estradiol, as the alveoli were found more regular. 
These data are in line with those achieved by molecular 
and proteomic biology techniques, showing hormone 
signaling serial activation on mammary epithelium is re-
quired for morphogenesis progression, i.e., for mammary 
alveolus formation26.
Concerning the association between sexual hormones 
and breast cancer before menopause, its assessment is 
exceedingly difficult and hindered by the hormonal level 
fluctuation occurred over the menstrual cycle. The rela-
tionship between breast cancer and estrogen levels in pre-
menopausal women could not be clearly demonstrated, 
possibly because the latter are constantly above the limit 
required to stimulate a breast cancer growth27. In con-
trast, the short-term relationship between hormone re-
placement in postmenopausal women and breast cancer 
development is uncertain based on inconsistent results 
in several studies. In studies indicating increased risk, it 
is limited to the long term (> 5-10 years), being relatively 
small (RR: 1.2-1.5)28.
Thus, new studies following this line are warranted and 
their purpose should be to clarify the relationship between 
breast cancer and postmenopausal hormone therapy dose 
and duration.
CONCLUSION
Estradiol and medroxyprogesterone have a proliferative 
effect on mammary parenchyma, although prior estradiol 
administration changes the progestogen action on mam-
mary tissue in adult rats.
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